Caribou Biosciences, Inc. Increase (Decrease) in Accounts Payable
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Accounts Payable of -$2.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$423.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$2.22M, a 258.12% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.92M.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $561.00K.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2025 was $3.25M.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$354.00K, a 119.46% decline from fiscal 2023.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.82M.
- Caribou Biosciences, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$2.72M, a 338.89% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$423.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.64M 10-Q · filed 2026-08-13 | -$724.00K derived: sum of 3 quarters · filed 2026-08-13 | -$163.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.22M 10-Q · filed 2026-05-07 | -$301.00K derived: sum of 2 quarters · filed 2026-05-07 | $260.00K derived: sum of 3 quarters · filed 2026-05-07 | -$370.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.48M derived: sum of 2 quarters · filed 2026-03-05 | $1.85M derived: sum of 3 quarters · filed 2026-08-13 | $3.25M 10-K · filed 2026-03-05 |
| 2025-09-30 | $561.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$69.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.33M 10-Q · filed 2025-11-12 | $1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$630.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $774.00K 10-Q · filed 2026-08-13 | $545.00K derived: sum of 3 quarters · filed 2026-08-13 | $68.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-07 | $1.18M derived: sum of 2 quarters · filed 2026-05-07 | $698.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$706.00K derived: sum of 2 quarters · filed 2026-03-05 | -$3.07M derived: sum of 3 quarters · filed 2026-03-05 | -$354.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.85M derived: sum of 2 quarters · filed 2025-11-12 | -$125.00K 10-Q · filed 2025-11-12 | $605.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $352.00K 10-Q · filed 2025-08-12 | $1.08M derived: sum of 3 quarters · filed 2025-08-12 | $129.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.72M 10-Q · filed 2025-05-08 | $3.45M derived: sum of 2 quarters · filed 2025-05-08 | $2.50M derived: sum of 3 quarters · filed 2025-05-08 | $3.04M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $730.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$223.00K derived: sum of 2 quarters · filed 2025-03-10 | $317.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.82M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$953.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$413.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.09M 10-Q · filed 2024-11-06 | $936.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $540.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.04M 10-Q · filed 2024-08-06 | $1.89M derived: sum of 3 quarters · filed 2024-08-06 | $2.88M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-07 | $1.35M derived: sum of 2 quarters · filed 2024-05-07 | $2.34M derived: sum of 3 quarters · filed 2024-05-07 | $696.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $836.00K derived: sum of 2 quarters · filed 2024-03-11 | -$806.00K derived: sum of 3 quarters · filed 2024-03-11 | -$2.72M 10-K · filed 2024-03-11 |
| 2022-09-30 | $989.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$653.00K derived: sum of 2 quarters · filed 2023-11-07 | -$2.57M 10-Q · filed 2023-11-07 | -$2.28M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.56M 10-Q · filed 2023-08-08 | -$3.27M derived: sum of 3 quarters · filed 2023-08-08 | -$3.45M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.92M 10-Q · filed 2023-05-09 | -$1.62M derived: sum of 2 quarters · filed 2023-05-09 | -$1.81M derived: sum of 3 quarters · filed 2023-05-09 | -$813.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $108.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.10M derived: sum of 3 quarters · filed 2023-03-09 | $1.14M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $811.00K derived: sum of 2 quarters · filed 2022-11-08 | $848.00K 10-Q · filed 2022-11-08 | $2.80M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $994.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.03M 10-Q · filed 2022-08-09 | $2.98M derived: sum of 3 quarters · filed 2022-08-09 | $756.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-09 | $1.99M derived: sum of 2 quarters · filed 2022-05-09 | -$238.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$275.00K derived: sum of 2 quarters · filed 2022-03-21 | $43.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.91M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $318.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $1.18M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |